The Ohio State University, United States.
Dr. Jessica L. Fleming, PhD, is an accomplished radiobiologist at the James Comprehensive Cancer Center, The Ohio State University. With over a decade of experience in translational oncology research, she specializes in molecular biomarkers and radiation therapy innovations. Dr. Fleming plays a key role in collaborative clinical and research initiatives, especially in glioma and FLASH radiotherapy. She is also a co-founder and former CEO of the Cap City Biohackers, demonstrating her entrepreneurial edge in biomedical innovation.
Profile
🎓 Education
Dr. Fleming earned her PhD in Molecular, Cellular, and Developmental Biology from The Ohio State University in 2012, following a BS in Biology, Cum Laude, from Ashland University in 2006. Her strong academic foundation was supported by multiple fellowships and research opportunities during her undergraduate and graduate studies.
🧪 Experience
Dr. Fleming currently serves as an Associate Radiobiologist at OSU, working with Dr. Arnab Chakravarti. Her journey at OSU began as a graduate student, advancing through postdoctoral research and senior research associate roles. She has led cutting-edge radiobiological studies and was integral to several major clinical protocols. Beyond academia, she was the CEO and Co-Founder of Cap City Biohackers, reflecting her commitment to science outreach and innovation.
🔬 Research Interests
Radiation oncology and molecular oncology, particularly adult gliomas and biomarkers
FLASH radiotherapy, clinical translation, and toxicity modeling
Tumor heterogeneity and resistance mechanisms
Translational research bridging lab discoveries and patient care
🏆 Awards & Honors
🥇 2024 ASTRO Annual Meeting Abstract Award
🏅 Columbus CEO Future 50 Award (2020)
🎖 Best of ASTRO & Basic/Translational Science Abstract Award (2018)
🎓 Alumni Grants for Graduate Research (2012)
🧬 NSF REU Fellow (2005)
🌟 Track & Field Athletic Scholar and Presidential Scholar (2002–2006)
📚 Selected Publications
Here are some of Dr. Fleming’s key publications, with citation and access details:
Fleming JL et al. (2025) – Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813 – Int J Radiat Oncol Biol Phys (Accepted)
Manring HR, Fleming JL et al. (2025) – FLASH Radiotherapy: From In Vivo Data to Clinical Translation – Hematol Oncol Clin N Am (PMID: 39828472)
Fleming JL, Chakravarti A. (2025) – Molecular Biomarkers in Adult Lower-Grade Gliomas – Cancer J, 31(1): e0758. (PMID: 39841423)
➤ Cited by: 2 articles
Kotecha R, Schiff D, Chakravarti A, Fleming JL et al. (2024) – Management of IDH-Mutated Gliomas – J Clin Oncol, 42(21): 2588-2598. (PMID: 38833641)
➤ Cited by: 15 articles
Becker AP, Becker V, McElroy J, Fleming J et al. (2024) – HMGB2 as Biomarker in Astrocytomas – Cancers (Basel), 16(8): 1516. (PMID: 38672598)
➤ Cited by: 7 articles